Circulating Tumor Cells Market Size, Share & Trends Analysis Report By Application (Clinical, Research), By Specimen (Bone Marrow, Blood), By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
Circulating Tumor Cells Market Growth & Trends
The global circulating tumor cells market size is estimated treach USD 24.96 billion by 2030, expanding at a CAGR of 12.2% from 2025 t2030, according ta new report by Grand View Research, Inc. This is attributed trising prevalence of cancer worldwide, increasing demand for non-invasive cancer diagnostic tools, and advancements in circulating tumor cells (CTC) technologies.
In recent years, CTCs are increasingly used for determining the prognosis of cancer and helping clinicians decide the type of therapy required for cancer treatment. CTCs have wide applications in several areas of cancer management—early detection of cancer, risk assessment of cancer recurrence, guidance for therapies, and continuous monitoring of a patient during cancer treatment. The development of various tumor markers utilizing CTCs, which can be used tdiagnose or monitor cancer, is expected tboost the adoption of CTCs over the forecast period. Therefore, it can be concluded that the detection of CTCs in the peripheral blood of patients with cancer acts as a promising diagnostic tool. For instance, quantitation and genomic profiling of CTCs enables cost-effective & accurate noninvasive monitoring of prostate cancer. The detection of CTCs is predictive for survival of cancer patients.
The limited applicability of these cells in rare cancers has hampered revenue growth ta certain extent. Circulating tumor cells are not applicable ttumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating tovercome these challenges in the near future.
However, in recent years, there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms tadvance the formation of a value chain and speed up the CTC market’s growth. For instance, in June 2023, tdevelop a novel test for the detection of tumor cells that metastatic cancers shed intthe blood, the University of Washington School of Medicine collaborated with RareCyte, Inc., which is a biotech company headquartered in Seattle. In addition, according tthe research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.
Circulating Tumor Cells Market Report Highlights
Circulating Tumor Cells Market Growth & Trends
The global circulating tumor cells market size is estimated treach USD 24.96 billion by 2030, expanding at a CAGR of 12.2% from 2025 t2030, according ta new report by Grand View Research, Inc. This is attributed trising prevalence of cancer worldwide, increasing demand for non-invasive cancer diagnostic tools, and advancements in circulating tumor cells (CTC) technologies.
In recent years, CTCs are increasingly used for determining the prognosis of cancer and helping clinicians decide the type of therapy required for cancer treatment. CTCs have wide applications in several areas of cancer management—early detection of cancer, risk assessment of cancer recurrence, guidance for therapies, and continuous monitoring of a patient during cancer treatment. The development of various tumor markers utilizing CTCs, which can be used tdiagnose or monitor cancer, is expected tboost the adoption of CTCs over the forecast period. Therefore, it can be concluded that the detection of CTCs in the peripheral blood of patients with cancer acts as a promising diagnostic tool. For instance, quantitation and genomic profiling of CTCs enables cost-effective & accurate noninvasive monitoring of prostate cancer. The detection of CTCs is predictive for survival of cancer patients.
The limited applicability of these cells in rare cancers has hampered revenue growth ta certain extent. Circulating tumor cells are not applicable ttumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating tovercome these challenges in the near future.
However, in recent years, there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms tadvance the formation of a value chain and speed up the CTC market’s growth. For instance, in June 2023, tdevelop a novel test for the detection of tumor cells that metastatic cancers shed intthe blood, the University of Washington School of Medicine collaborated with RareCyte, Inc., which is a biotech company headquartered in Seattle. In addition, according tthe research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.
Circulating Tumor Cells Market Report Highlights
- Based on technology, The CTC detection and enrichment methods segment accounted for the largest revenue share of 40.92% in 2024 owing tthe increased availability of products for CTC enrichment and isolation as well as high usage and product penetration across the globe
- CTC analysis is expected tregister the fastest CAGR during the forecast period due tthe growing application potential of CTC analysis for investigational research, drug development, and biomarker studies
- Based on application, the research segment dominated the market in 2024 and it is expected twitness the fastest CAGR from 2025 t2030
- Kits & reagent dominated the product segment in 2024, and it is expected twitness the fastest growth in forecast period of 2025-2030
- Based on specimen, the blood segment dominated the market in 2024. The other body fluids segment is expected twitness the fastest CAGR from 2025 t2030
- Based on end-use, the research & academic institutes segment dominated the market in 2024 due tincreasing focus on research and development activities for cancer diagnosis and treatment
- North America dominated the CTC market in 2024, owing tfactors such as the presence of key market players Bio-Techne Corporation, Precision Medicine Group LLC, Epic Sciences, APPLIED DNA SCIENCES, INC., and LungLife AI, Inc. and the growth in pharmaceutical & biotechnology research sectors in this region
- Asia Pacific is expected tregister the fastest CAGR over the forecast period due tseveral companies expanding their presence in countries like Japan
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Application
1.2.3. Product
1.2.4. Specimen
1.2.5. End use
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. CIRCULATING TUMOR CELLS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Advancements in chip technology
3.2.1.2. Expanding applications of CTCs
3.2.1.3. Growing demand for early and rapid cancer diagnosis
3.2.1.4. Growing incidence of cancer
3.2.2. Market restraint analysis
3.2.2.1. Consistency-related challenges in CTC detection and enrichment
3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
3.2.2.3. Lower applicability of CTCs in rare cancers
3.3. Circulating Tumor Cells Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. CIRCULATING TUMOR CELLS MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
4.1. Technology Segment Dashboard
4.2. Global Circulating Tumor Cells Market Technology Movement Analysis
4.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. CTC Detection & Enrichment Methods
4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2. Immunocapture (Label-based)
4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2.2. Positive Selection
4.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2.3. Negative Selection
4.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3. Size-based Separation (Label-free)
4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3.2. Membrane-based
4.4.1.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3.3. Microfluidic-based
4.4.1.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.4. Density-based Separation (Label-free)
4.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.5. Combined Methods
4.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2. CTC Direct Detection Methods
4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2.2. SERS
4.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2.3. Microscopy
4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2.4. Others
4.4.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.3. CTC Analysis
4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 5. CIRCULATING TUMOR CELLS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Application Segment Dashboard
5.2. Global Circulating Tumor Cells Market Application Movement Analysis
5.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Clinical
5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.1.2. Risk Assessment
5.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.1.3. Screening and Monitoring
5.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2. Research
5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2.2. Cancer Stem Cell & Tumorogenesis Research
5.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2.3. Drug/Therapy Development
5.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 6. CIRCULATING TUMOR CELLS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
6.1. Product Segment Dashboard
6.2. Global Circulating Tumor Cells Market Product Movement Analysis
6.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Kits & reagents
6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
6.4.2. Blood collection tubes
6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3. Devices or systems
6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 7. CIRCULATING TUMOR CELLS MARKET: SPECIMEN ESTIMATES & TREND ANALYSIS
7.1. Specimen Segment Dashboard
7.2. Global Circulating Tumor Cells Market Specimen Movement Analysis
7.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Blood
7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
7.4.2. Bone marrow
7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. Other body fluids
7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 8. CIRCULATING TUMOR CELLS MARKET: END USE ESTIMATES & TREND ANALYSIS
8.1. End Use Segment Dashboard
8.2. Global Circulating Tumor Cells Market End Use Movement Analysis
8.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Research and academic institutes
8.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
8.4.2. Hospital and clinics
8.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.4.3. Diagnostic centers
8.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 9. CIRCULATING TUMOR CELLS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
9.1. Regional Market Share Analysis, 2024 & 2030
9.2. Regional Market Dashboard
9.3. North America
9.3.1. U.S.
9.3.1.1. Key country dynamics
9.3.1.2. Regulatory framework
9.3.1.3. Competitive scenario
9.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
9.3.1.5. Target disease prevalence
9.3.2. Canada
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework
9.3.2.3. Competitive scenario
9.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
9.3.2.5. Target disease prevalence
9.3.3. Mexico
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework
9.3.3.3. Competitive scenario
9.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
9.3.3.5. Target disease prevalence
9.4. Europe
9.4.1. UK
9.4.1.1. Key country dynamics
9.4.1.2. Regulatory framework
9.4.1.3. Competitive scenario
9.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
9.4.1.5. Target disease prevalence
9.4.2. Germany
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework
9.4.2.3. Competitive scenario
9.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
9.4.2.5. Target disease prevalence
9.4.3. France
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework
9.4.3.3. Competitive scenario
9.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
9.4.3.5. Target disease prevalence
9.4.4. Italy
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework
9.4.4.3. Competitive scenario
9.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
9.4.4.5. Target disease prevalence
9.4.5. Spain
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework
9.4.5.3. Competitive scenario
9.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
9.4.5.5. Target disease prevalence
9.4.6. Norway
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework
9.4.6.3. Competitive scenario
9.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
9.4.6.5. Target disease prevalence
9.4.7. Sweden
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework
9.4.7.3. Competitive scenario
9.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
9.4.7.5. Target disease prevalence
9.4.8. Denmark
9.4.8.1. Key country dynamics
9.4.8.2. Regulatory framework
9.4.8.3. Competitive scenario
9.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
9.4.8.5. Target disease prevalence
9.5. Asia Pacific
9.5.1. Japan
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework
9.5.1.3. Competitive scenario
9.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
9.5.1.5. Target disease prevalence
9.5.2. China
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
9.5.2.5. Target disease prevalence
9.5.3. India
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
9.5.3.5. Target disease prevalence
9.5.4. Australia
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
9.5.4.5. Target disease prevalence
9.5.5. South Korea
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework
9.5.5.3. Competitive scenario
9.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
9.5.5.5. Target disease prevalence
9.5.6. Thailand
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework
9.5.6.3. Competitive scenario
9.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
9.5.6.5. Target disease prevalence
9.6. Latin America
9.6.1. Brazil
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework
9.6.1.3. Competitive scenario
9.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
9.6.1.5. Target disease prevalence
9.6.2. Argentina
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework
9.6.2.3. Competitive scenario
9.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
9.6.2.5. Target disease prevalence
9.7. MEA
9.7.1. South Africa
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework
9.7.1.3. Competitive scenario
9.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
9.7.1.5. Target disease prevalence
9.7.2. Saudi Arabia
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework
9.7.2.3. Competitive scenario
9.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
9.7.2.5. Target disease prevalence
9.7.3. UAE
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework
9.7.3.3. Competitive scenario
9.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
9.7.3.5. Target disease prevalence
9.7.4. Kuwait
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework
9.7.4.3. Competitive scenario
9.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
9.7.4.5. Target disease prevalence
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company position analysis, 2024
10.3.4. QIAGEN
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Product benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Bio-Techne Corp.
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Product benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Precision Medicine Group, LLC.
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Product benchmarking
10.3.6.4. Strategic initiatives
10.3.7. Bio-Rad Laboratories, Inc.
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Product benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Natera, Inc.
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Product benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Illumina, Inc.
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Product benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Cell Microsystems
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Product benchmarking
10.3.10.4. Strategic initiatives
10.3.11. Greiner Bio One International GmbH
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Product benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Ikonisys Inc.
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Product benchmarking
10.3.12.4. Strategic initiatives
10.3.13. Miltenyi Biotec
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Product benchmarking
10.3.13.4. Strategic initiatives
10.3.14. Creative Bioarray
10.3.14.1. Company overview
10.3.14.2. Financial performance
10.3.14.3. Product benchmarking
10.3.14.4. Strategic initiatives
10.3.15. BioFluidica
10.3.15.1. Company overview
10.3.15.2. Financial performance
10.3.15.3. Product benchmarking
10.3.15.4. Strategic initiatives
10.3.16. Abnova Corporation
10.3.16.1. Company overview
10.3.16.2. Financial performance
10.3.16.3. Product benchmarking
10.3.16.4. Strategic initiatives
10.3.17. Biolidics Limited
10.3.17.1. Company overview
10.3.17.2. Financial performance
10.3.17.3. Product benchmarking
10.3.17.4. Strategic initiatives
10.3.18. Creativ MicroTech, Inc.
10.3.18.1. Company overview
10.3.18.2. Financial performance
10.3.18.3. Product benchmarking
10.3.18.4. Strategic initiatives
10.3.19. LungLife AI
10.3.19.1. Company overview
10.3.19.2. Financial performance
10.3.19.3. Product benchmarking
10.3.19.4. Strategic initiatives
10.3.20. Epic Sciences
10.3.20.1. Company overview
10.3.20.2. Financial performance
10.3.20.3. Product benchmarking
10.3.20.4. Strategic initiatives
10.3.21. Rarecells Diagnostics
10.3.21.1. Company overview
10.3.21.2. Financial performance
10.3.21.3. Product benchmarking
10.3.21.4. Strategic initiatives
10.3.22. ScreenCell
10.3.22.1. Company overview
10.3.22.2. Financial performance
10.3.22.3. Product benchmarking
10.3.22.4. Strategic initiatives
10.3.23. Menarini Silicon Biosystems
10.3.23.1. Company overview
10.3.23.2. Financial performance
10.3.23.3. Product benchmarking
10.3.23.4. Strategic initiatives
10.3.24. APPLIED DNA SCIENCES, INC.
10.3.24.1. Company overview
10.3.24.2. Financial performance
10.3.24.3. Product benchmarking
10.3.24.4. Strategic initiatives
10.3.25. Sysmex Corporation
10.3.25.1. Company overview
10.3.25.2. Financial performance
10.3.25.3. Product benchmarking
10.3.25.4. Strategic initiatives
10.3.26. STEMCELL Technologies, Inc.
10.3.26.1. Company overview
10.3.26.2. Financial performance
10.3.26.3. Product benchmarking
10.3.26.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Application
1.2.3. Product
1.2.4. Specimen
1.2.5. End use
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. CIRCULATING TUMOR CELLS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Advancements in chip technology
3.2.1.2. Expanding applications of CTCs
3.2.1.3. Growing demand for early and rapid cancer diagnosis
3.2.1.4. Growing incidence of cancer
3.2.2. Market restraint analysis
3.2.2.1. Consistency-related challenges in CTC detection and enrichment
3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
3.2.2.3. Lower applicability of CTCs in rare cancers
3.3. Circulating Tumor Cells Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. CIRCULATING TUMOR CELLS MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
4.1. Technology Segment Dashboard
4.2. Global Circulating Tumor Cells Market Technology Movement Analysis
4.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. CTC Detection & Enrichment Methods
4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2. Immunocapture (Label-based)
4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2.2. Positive Selection
4.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.2.3. Negative Selection
4.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3. Size-based Separation (Label-free)
4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3.2. Membrane-based
4.4.1.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.3.3. Microfluidic-based
4.4.1.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.4. Density-based Separation (Label-free)
4.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.1.5. Combined Methods
4.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2. CTC Direct Detection Methods
4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2.2. SERS
4.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2.3. Microscopy
4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2.4. Others
4.4.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.3. CTC Analysis
4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 5. CIRCULATING TUMOR CELLS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Application Segment Dashboard
5.2. Global Circulating Tumor Cells Market Application Movement Analysis
5.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Clinical
5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.1.2. Risk Assessment
5.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.1.3. Screening and Monitoring
5.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2. Research
5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2.2. Cancer Stem Cell & Tumorogenesis Research
5.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.4.2.3. Drug/Therapy Development
5.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 6. CIRCULATING TUMOR CELLS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
6.1. Product Segment Dashboard
6.2. Global Circulating Tumor Cells Market Product Movement Analysis
6.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Kits & reagents
6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
6.4.2. Blood collection tubes
6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.4.3. Devices or systems
6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 7. CIRCULATING TUMOR CELLS MARKET: SPECIMEN ESTIMATES & TREND ANALYSIS
7.1. Specimen Segment Dashboard
7.2. Global Circulating Tumor Cells Market Specimen Movement Analysis
7.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Blood
7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
7.4.2. Bone marrow
7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. Other body fluids
7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 8. CIRCULATING TUMOR CELLS MARKET: END USE ESTIMATES & TREND ANALYSIS
8.1. End Use Segment Dashboard
8.2. Global Circulating Tumor Cells Market End Use Movement Analysis
8.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Research and academic institutes
8.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
8.4.2. Hospital and clinics
8.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.4.3. Diagnostic centers
8.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 9. CIRCULATING TUMOR CELLS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
9.1. Regional Market Share Analysis, 2024 & 2030
9.2. Regional Market Dashboard
9.3. North America
9.3.1. U.S.
9.3.1.1. Key country dynamics
9.3.1.2. Regulatory framework
9.3.1.3. Competitive scenario
9.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
9.3.1.5. Target disease prevalence
9.3.2. Canada
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework
9.3.2.3. Competitive scenario
9.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
9.3.2.5. Target disease prevalence
9.3.3. Mexico
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework
9.3.3.3. Competitive scenario
9.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
9.3.3.5. Target disease prevalence
9.4. Europe
9.4.1. UK
9.4.1.1. Key country dynamics
9.4.1.2. Regulatory framework
9.4.1.3. Competitive scenario
9.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
9.4.1.5. Target disease prevalence
9.4.2. Germany
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework
9.4.2.3. Competitive scenario
9.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
9.4.2.5. Target disease prevalence
9.4.3. France
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework
9.4.3.3. Competitive scenario
9.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
9.4.3.5. Target disease prevalence
9.4.4. Italy
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework
9.4.4.3. Competitive scenario
9.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
9.4.4.5. Target disease prevalence
9.4.5. Spain
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework
9.4.5.3. Competitive scenario
9.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
9.4.5.5. Target disease prevalence
9.4.6. Norway
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework
9.4.6.3. Competitive scenario
9.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
9.4.6.5. Target disease prevalence
9.4.7. Sweden
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework
9.4.7.3. Competitive scenario
9.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
9.4.7.5. Target disease prevalence
9.4.8. Denmark
9.4.8.1. Key country dynamics
9.4.8.2. Regulatory framework
9.4.8.3. Competitive scenario
9.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
9.4.8.5. Target disease prevalence
9.5. Asia Pacific
9.5.1. Japan
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework
9.5.1.3. Competitive scenario
9.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
9.5.1.5. Target disease prevalence
9.5.2. China
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
9.5.2.5. Target disease prevalence
9.5.3. India
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
9.5.3.5. Target disease prevalence
9.5.4. Australia
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
9.5.4.5. Target disease prevalence
9.5.5. South Korea
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework
9.5.5.3. Competitive scenario
9.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
9.5.5.5. Target disease prevalence
9.5.6. Thailand
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework
9.5.6.3. Competitive scenario
9.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
9.5.6.5. Target disease prevalence
9.6. Latin America
9.6.1. Brazil
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework
9.6.1.3. Competitive scenario
9.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
9.6.1.5. Target disease prevalence
9.6.2. Argentina
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework
9.6.2.3. Competitive scenario
9.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
9.6.2.5. Target disease prevalence
9.7. MEA
9.7.1. South Africa
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework
9.7.1.3. Competitive scenario
9.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
9.7.1.5. Target disease prevalence
9.7.2. Saudi Arabia
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework
9.7.2.3. Competitive scenario
9.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
9.7.2.5. Target disease prevalence
9.7.3. UAE
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework
9.7.3.3. Competitive scenario
9.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
9.7.3.5. Target disease prevalence
9.7.4. Kuwait
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework
9.7.4.3. Competitive scenario
9.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
9.7.4.5. Target disease prevalence
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company position analysis, 2024
10.3.4. QIAGEN
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Product benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Bio-Techne Corp.
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Product benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Precision Medicine Group, LLC.
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Product benchmarking
10.3.6.4. Strategic initiatives
10.3.7. Bio-Rad Laboratories, Inc.
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Product benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Natera, Inc.
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Product benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Illumina, Inc.
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Product benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Cell Microsystems
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Product benchmarking
10.3.10.4. Strategic initiatives
10.3.11. Greiner Bio One International GmbH
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Product benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Ikonisys Inc.
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Product benchmarking
10.3.12.4. Strategic initiatives
10.3.13. Miltenyi Biotec
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Product benchmarking
10.3.13.4. Strategic initiatives
10.3.14. Creative Bioarray
10.3.14.1. Company overview
10.3.14.2. Financial performance
10.3.14.3. Product benchmarking
10.3.14.4. Strategic initiatives
10.3.15. BioFluidica
10.3.15.1. Company overview
10.3.15.2. Financial performance
10.3.15.3. Product benchmarking
10.3.15.4. Strategic initiatives
10.3.16. Abnova Corporation
10.3.16.1. Company overview
10.3.16.2. Financial performance
10.3.16.3. Product benchmarking
10.3.16.4. Strategic initiatives
10.3.17. Biolidics Limited
10.3.17.1. Company overview
10.3.17.2. Financial performance
10.3.17.3. Product benchmarking
10.3.17.4. Strategic initiatives
10.3.18. Creativ MicroTech, Inc.
10.3.18.1. Company overview
10.3.18.2. Financial performance
10.3.18.3. Product benchmarking
10.3.18.4. Strategic initiatives
10.3.19. LungLife AI
10.3.19.1. Company overview
10.3.19.2. Financial performance
10.3.19.3. Product benchmarking
10.3.19.4. Strategic initiatives
10.3.20. Epic Sciences
10.3.20.1. Company overview
10.3.20.2. Financial performance
10.3.20.3. Product benchmarking
10.3.20.4. Strategic initiatives
10.3.21. Rarecells Diagnostics
10.3.21.1. Company overview
10.3.21.2. Financial performance
10.3.21.3. Product benchmarking
10.3.21.4. Strategic initiatives
10.3.22. ScreenCell
10.3.22.1. Company overview
10.3.22.2. Financial performance
10.3.22.3. Product benchmarking
10.3.22.4. Strategic initiatives
10.3.23. Menarini Silicon Biosystems
10.3.23.1. Company overview
10.3.23.2. Financial performance
10.3.23.3. Product benchmarking
10.3.23.4. Strategic initiatives
10.3.24. APPLIED DNA SCIENCES, INC.
10.3.24.1. Company overview
10.3.24.2. Financial performance
10.3.24.3. Product benchmarking
10.3.24.4. Strategic initiatives
10.3.25. Sysmex Corporation
10.3.25.1. Company overview
10.3.25.2. Financial performance
10.3.25.3. Product benchmarking
10.3.25.4. Strategic initiatives
10.3.26. STEMCELL Technologies, Inc.
10.3.26.1. Company overview
10.3.26.2. Financial performance
10.3.26.3. Product benchmarking
10.3.26.4. Strategic initiatives
